Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Essential Hypertension Vascular Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

About this study

Non Probability Sampling

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male and Female patients 18 to 65 y/old
Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP
Patient with uncontrolled mild to moderate hypertension (SBP>= 140 and <=179 mmHg OR DBP of >=90 and <=109 mmHg)

Exclusion criteria

Pregnant of Lactating women
History of secondary hypertension

Treatment and study plan

olmesartan medoxomil

Drug

olmesartan medoxomil 20 mg and HCTZ 12.5 mg

Primary outcomes

Safety (Adverse Events)

Time frame: 4 weeks

Secondary outcomes

Blood Pressure

Time frame: 4 weeks

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension

Important dates

Study start: 2007
Primary completion: 2008
Study completion: 2008
First posted: Nov 24, 2008
Registry last updated: Dec 23, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed